Stock Ratings / Health Care / CELZ / earnings

BTTC (48) LIMN (45) CRIS (40) PMCB (40) ⌘ Pro Terminal →

Creative Medical Technology Holdings Inc. (CELZ) Next Earnings Date & Expected ±12.5% Move

Q: When is CELZ's next earnings date?

Based on SEC filing cadence, Creative Medical Technology Holdings Inc. (CELZ)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is CELZ stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for CELZ, spanning a range between $1 and $0.77.

$0.68 -5.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Creative Medical Technology Holdings Inc. (CELZ) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CELZ)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.09 Expected Swing

MODEL EARNINGS SETUP GAUGE

CELZ Quantitative Pre-Earnings Setup: 27/100

Trailing EPS: $4.25 • YoY Revenue Growth: -45.5%

Model Bullish Setup (27/100)Model Risk Weight (73/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$6.0K	-$6.0M	-$5.9M	63.4%
FY 2024	2024-12-31	$11.0K	-$5.5M	-$5.3M	60%
FY 2023	2023-12-31	$9.0K	-$5.3M	-$8.0M	63.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CELZ)

✓Walkthrough of CELZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CELZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -69.78%▼ DESCENDING CHANNEL

2026-10-30O $0.72H $0.72L $0.65C $0.68VOL 87.0K

RES: $1.04SUP: $-0.99SMA50: $0.93SMA200: $1.58

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CELZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CELZ Butterfly Map → + Track CELZ →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CELZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CELZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CELZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CELZ)

Health Care Rank #981 of 1016 ⚔️ BTTC vs CELZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CELZ vs. BTTC, LIMN, CRIS, PMCB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Creative Medical Technology Holdings Inc. (CELZ) ranks #981 by composite RQD confidence (27/100, grade E) and #945 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, CELZ leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with CELZ at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CELZ ACTIVE Creative Medical Technology Holdings Inc.	E	27/100	—	63.4%	-35.0%	-5.78%	$5.2M	Benchmark Subject
BTTC Black Titan Corporation	D	48/100	—	—	—	+4.23%	$5.3M	/bttc-vs-celz →
LIMN Liminatus Pharma Inc. (Class A)	D	45/100	—	—	-35.0%	-0.86%	$3.9M	/limn-vs-celz →
CRIS Curis Inc.	D-	40/100	—	—	-35.0%	+20.82%	$3.7M	/cris-vs-celz →
PMCB PharmaCyte Biotech Inc.	D-	40/100	—	—	-30.2%	-0.78%	$3.6M	/pmcb-vs-celz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001187953

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Creative Medical Technology Holdings Inc. (CELZ) reported GAAP revenue of $6.0K (-45.5% vs. FY2024 revenue of $11.0K , and -33.3% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (-10.5% YoY). On the balance sheet, CELZ closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.0K	-$6.0M	-$5.9M	-$5.9M	$7.8M	—
FY2024 (FY)	2024-12-31	$11.0K	-$5.5M	-$5.3M	-$5.3M	$6.7M	—
FY2023 (FY)	2023-12-31	$9.0K	-$5.3M	-$8.0M	-$8.0M	—	—

3. CELZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CELZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $0.68 (-5.78% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CELZ ranks #981 in composite RQD confidence.

How does CELZ compare to BTTC and LIMN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CELZ carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 63.4%, and ROIC of -35.0%. By comparison, BTTC (Black Titan Corporation) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M). Among the 5-stock peer group, CELZ leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CELZ?

Per CELZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001187953), Creative Medical Technology Holdings Inc. generated $6.0K in revenue (-45.5% YoY), -$6.0M in net income, and -$5.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CELZ trading relative to its 50-day, 200-day, and 52-week technical levels?

CELZ last traded at $0.68 (-5.78% on volume of 62,653 shares), positioning the stock -26.88% below its 50-day simple moving average ($0.93) and -56.96% below its 200-day simple moving average ($1.58). Across its 52-week range of $0.62 to $4.72, CELZ sits at the 1.5% percentile with a 14-day RSI of 31.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.77).